Optimization of the thrombin generation test components to measure potency of factor VIII concentrates

Haemophilia

Volumn 22, Issue 5, 2016, Pages 780-789

  Jha, N K ^a,b   Shestopal, S A ^a   Gourley, M J ^a   Woodle, S A ^a   Liang, Y ^a   Sarafanov, A G ^a   Weinstein, M ^a   Ovanesov, M V ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

factor VIII; haemophilia; potency; thrombin generation test

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HEPARIN; THROMBOMODULIN;

ARTICLE; CONCENTRATION (PARAMETERS); DILUTION; HEMOPHILIA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; THROMBIN TIME; VELOCITY;

EID: 84990192499     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12943     Document Type: Article

References (44)

1. Klintman J, Berntorp E, Astermark J. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2010; 16: e210–5.
2. van Veen JJ, Gatt A, Bowyer AE et al. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009; 31: 189–98.
3. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326–34.
4. Dargaud Y, Lienhart A, Meunier S et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552–8.
5. Hemker HC, Giesen P, Al Dieri R et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249–53.
6. Salvagno GL, Berntorp E. Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost 2010; 36: 780–90.
7. Foley JH, Orfeo T, Undas A et al. From principle to practice: bridging the gap in patient profiling. PLoS ONE 2013; 8: e54728.
8. Young G, Sorensen B, Dargaud Y et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121: 1944–50.
9. Buyue Y, Liu T, Kulman JD et al. A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity. PLoS ONE 2014; 9: e113600.
10. Butenas S, Parhami-Seren B, Gissel MT et al. Potency and mass of factor VIII in FVIII products. Haemophilia 2009; 15: 63–72.
11. Christiansen ML, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878–87.
12. McIntosh JH, Owens D, Lee CA et al. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003; 1: 1005–11.
13. Ninivaggi M, Dargaud Y, van Oerle R et al. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost 2011; 9: 1549–55.
14. Zollner SB, Raquet E, Muller-Cohrs J et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 2013; 132: 280–7.
15. Matsumoto T, Nogami K, Ogiwara K et al. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol 2009; 90: 576–82.
16. Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem 2002; 277: 50439–44.
17. Woodle SA, Shibeko AM, Lee TK et al. Determining the impact of instrument variation and automated software algorithms on the TGT in hemophilia and normalized plasma. Thromb Res 2013; 132: 374–80.
18. Ekezue BF, Sridhar G, Ovanesov MV et al. Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in large healthcare database during 2008-2013. J Thromb Haemost 2015; 10: 2168–79.
19. Parunov LA, Surov SS, Tucker E et al. The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood: comment. J Thromb Haemost 2015; 13: 1527–30.
20. Hemker HC, Giesen P, Al DR et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4–15.
21. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989; 62: 788–91.
22. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889–903.
23. De Smedt E, Wagenvoord R, Hemker CH. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thromb Haemost 2009; 101: 165–70.
24. Parmar N, Berry LR, Paredes N et al. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA. Clin Lab 2005; 51: 157–66.
25. Manco-Johnson MJ, Nuss R, Jacobson LJ. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 2000; 136: 74–9.
26. Dielis AW, Balliel WM, van Oerle R et al. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. Haematologica 2008; 93: 1351–7.
27. Liang Y, Woodle SA, Shibeko AM et al. Correction of microplate location effects improves performance of the thrombin generation test. Thromb J 2013; 11: 12.
28. Whelihan MF, Orfeo T, Gissel MT et al. Coagulation procofactor activation by factor XIa. J Thromb Haemost 2010; 8: 1532–9.
29. Dodt J, Hubbard AR, Wicks SJ et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
30. Gu JM, Ramsey P, Evans V et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20: 593–600.
31. Sommer JM, Moore N, McGuffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
32. Viuff D, Barrowcliffe T, Saugstrup T et al. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695–702.
33. Pouplard C, Caron C, Aillaud MF et al. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII: C levels in ReFacto AF mock plasma samples by a one-stage clotting assay. Haemophilia 2011; 17: e958–62.
34. Rosen S. A rebuttal: issues with the assay of factor VIII activity in plasma and factor VII concentrates. Thromb Haemost 2001; 86: 1132–3.
35. Trossaert M, Lienhart A, Nougier C et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia 2014; 20: 550–8.
36. Al Hawaj MA, Martin EJ, Venitz J et al. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 2013; 19: 409–14.
37. Ay Y, Balkan C, Karapinar DY et al. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors. Haemophilia 2012; 18: 911–6.
38. Salinas V, Carmona R, Mohammed BM et al. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors? Haemophilia 2015; 21: 398–404.
39. Olsson A, Hellgren M, Berntorp E et al. Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation. Haemophilia 2015; 21: e111–3.
40. Haghpanah S, Bazrafshan A, Silavizadeh S et al. Evaluation of thrombin generation assay in patients with hemophilia. Clin Appl Thromb Hemost 2014; doi: 10.1177/1076029614555903.
41. Khanum F, Collins PW, Harris RL et al. Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay. Haemophilia 2014; 20: 287–93.
42. van Veen JJ, Gatt A, Bowyer AE et al. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res 2009; 123: 895–901.
43. Livnat T, Shenkman B, Martinowitz U et al. The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thromb Res 2015; 136: 465–73.
44. Waters EK, Hilden I, Sorensen BB et al. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive. J Thromb Haemost 2015; 13: 2041–52.